Gosset Seed Health General Information
Seed Health has developed a portfolio of clinically validated probiotic/synbiotic products such as DS‑01® Daily Synbiotic (for adults), PDS‑08® Pediatric Daily Synbiotic (for children), and VS‑01™ Vaginal Synbiotic. These have been tested in multiple double-blind randomized controlled trials showing efficacy in restoring optimal microbiomes in the gut or vagina. The company also collaborates on live biotherapeutic drug development targeting unmet needs in urogenital/reproductive health through LUCA Biologics. Their environmental arm develops microbial solutions to ecological challenges like honeybee preservation and coral reef regeneration. Revenue was estimated at $200M in FY2024 with rapid growth expected due to new product launches and retail expansion into Target stores nationwide.
Contact Information
United States
Drug Pipeline
Key Partnerships
Academic partnerships with Weizmann Institute of Science, University of Zurich/SIAF, University of Maryland School of Medicine, Fullscript distribution partnership, retail partnership with Target stores nationwide
Seed Health Funding
No funding data available